news on tirzepatide FDA Grants a New Indication for Obesity Management Tirzepatide vs. semaglutide: Study compares
Description
It reviews their mechanisms of action, semaglutide acting as a GLP-1 receptor agonist and tirzepatide functioning as a dual GIP/GLP-1 receptor agonist, and explains how these pathways translate into clinical outcomes
Ready to take the next step
The latest generation of anti-obesity drugs has taken the world by storm, thanks to their effectiveness at treating diabetes and reducing weight
If tirzepatide is discontinued, some or all of the lost weight may be regained, given how the medication works to regulate appetite and glucose metabolism
Helps support structured program documentation and care planning
Increases the risk of mental health disorders, including anxiety and depression
